[4-(4-Chloro-phenyl)-3-cyano-6-phenyl-pyridin-2-ylsulfanyl]-acetic acid | 94640-07-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [4-(4-Chloro-phenyl)-3-cyano-6-phenyl-pyridin-2-ylsulfanyl]-acetic acid
• 英文别名: 2-[4-(4-chlorophenyl)-3-cyano-6-phenylpyridin-2-yl]sulfanylacetic acid
• CAS: 94640-07-0
• 化学式: C₂₀H₁₃ClN₂O₂S
• 分子量: 380.854
• InChiKey: HLGHNIDFCLZGPX-UHFFFAOYSA-N

物化性质

• 沸点：
  598.2±50.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  99.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [4-(4-Chloro-phenyl)-3-cyano-6-phenyl-pyridin-2-ylsulfanyl]-acetic acid 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 4.5h， 以90%的产率得到3-Amino-4-(4-chlorphenyl)-6-phenylthieno<2,3-b>pyridin-2-carbonsaeure
  参考文献：
  名称：

  Shestopalov, A. M.; Sharanin, Yu. A., Journal of Organic Chemistry USSR (English Translation), 1984, p. 1818 - 1827

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(4-Chlor-phenyl)-6-phenyl-2-thioxo-1,2-dihydro-pyridin-3-carbonitril 、 potassium bromoacetate 在 氢氧化钾 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以63%的产率得到[4-(4-Chloro-phenyl)-3-cyano-6-phenyl-pyridin-2-ylsulfanyl]-acetic acid
  参考文献：
  名称：

  Shestopalov, A. M.; Sharanin, Yu. A., Journal of Organic Chemistry USSR (English Translation), 1984, p. 1818 - 1827

  摘要：

  DOI：

文献信息

• Glyoxalase inhibitors
  申请人：Ashton Mark

  公开号：US20070015799A1

  公开（公告）日：2007-01-18

  This invention relates to compounds of formula (I) which are glyoxalase I inhibitors, pharmaceutical salts or compositions comprising such compounds, and the use of such compositions and compounds to treat various conditions alleviated by the inhibition of glyoxalase 1. Wherein X is N or CH. R 2 is H, CF 3 ; or optionally substituted C 5-6 aryl, C 3-7 cycloalkyl, C 5-7 heterocyclyl. R 3 is H; or optionally substituted C 5-6 aryl, C 3-7 cycloalkyl, C 5-7 heterocyclyl. Alternatively R 2 and R 3 together form an optionally substituted C 3-4 alkylene group wherein L 3 and L 4 are single bonds thus forming a C 5-6 ring fused with the aromatic ring to which L 3 and L 4 are attached. L 3 and L 4 are independently selected from a single bond, optionally substituted C 1-4 alkylene, -L 9 YN(OH)C(═O)L 10 - and -L 9 C(═O)N(OH)YL 10 -, wherein L 9 and L 10 are independently selected from optionally substituted C 1-4 alkylene, C 5-6 arylene, C 1-4 alkylene-C 5-6 arylene and a single bond, wherein Y is NH or a single bond.

  本发明涉及式(I)的化合物，它们是乙二醛酶I抑制剂，包括此类化合物的药物盐或组合物，以及使用这种组合物和化合物来治疗通过抑制乙二醛酶1缓解的各种疾病。其中X是N或CH。R2为H、CF3；或者是可选取代的C5-6芳基、C3-7环烷基、C5-7杂环基。R3为H；或者是可选取代的C5-6芳基、C3-7环烷基、C5-7杂环基。或者R2和R3一起形成一个可选取代的C3-4烷基，其中L3和L4是单键，从而形成一个与L3和L4连接的芳环。L3和L4分别独立选择自单键、可选取代的C1-4烷基、-L9YN(OH)C(═O)L10-和-L9C(═O)N(OH)YL10-，其中L9和L10分别独立选择自可选取代的C1-4烷基、C5-6芳基、C1-4烷基-C5-6芳基和单键，其中Y为NH或单键。
• SHESTOPALOV, A. M.;SHARANIN, YU. A., ZH. ORGAN. XIMII, 1984, 20, N 9, 1991-2002
  作者：SHESTOPALOV, A. M.、SHARANIN, YU. A.

  DOI：——

  日期：——
• Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
  申请人：Mackerell Alexander

  公开号：US20070099970A1

  公开（公告）日：2007-05-03

  Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.
• Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
  申请人：Mackerell Alexander

  公开号：US20070196395A1

  公开（公告）日：2007-08-23

  Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.
• COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS
  申请人：Neamati Nouri

  公开号：US20090088420A1

  公开（公告）日：2009-04-02

  Pharmacophore models to be used in drug design and discovery are provided. An in silico protocol and in vitro assays are presented. Compounds and their pharmaceutically acceptable salts with HIV-1 integrase inhibitory and anti-HIV activity and use thereof in the treatment of HIV/AIDS and related infections either alone or in combination with all the known antiretroviral therapeutics are described.